MedTrace Logo

A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia

NCT04255680 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-08-18

No results posted yet for this study

Summary

To test the variability of specific ribonucleic acid (RNA) and proteins as well as frataxin levels in samples of blood and buccal cells taken directly from patients with Friedreich's ataxia (FRDA) in order to confirm potential new biomarkers of disease in patients with FRDA.

Conditions

  • Friedreich Ataxia

Interventions

DIAGNOSTIC_TEST

Buccal Swabs and Blood Draws

Buccal Swabs - Frataxin \& specific RNA markers Blood Draws - Lipid panel, Uric Acid, Protein Marker Analysis and PAX Gene RNA Analysis

Sponsors & Collaborators

Principal Investigators

  • David Lynch, M.D. · Children's Hospital of Philadelphia

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-14
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04255680 on ClinicalTrials.gov